Morten Sommer

Excited to share the research that lead to @sniprbiome development candidate for selective targeting of E. coli in the gut using #CRISPR armed #phages nature.com/articles/s4158…

Microbes are already used for food production, yet, their potential for making new healthy and sustainable foods is far from exhausted. Learn more about the Microbial Foods field here: authors.elsevier.com/a/1gRm4_278y%7… @CellCellPress @DTUBiosustain @novonordiskfond

Characterization of new #biosensors for E coli #Nissle to aid the design of Advanced #microbiome Therapeutics pubs.acs.org/doi/full/10.10…

Happy to share our collaborative work on the in vitro evaluation of Niclosamide in primary bronchial cells. #PLOSONE: Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a c ... dx.plos.org/10.1371/journa…

@DrJDennehy @mbiojournal @fabspagnolo Great review of our knowledge of the pre-antibiotic era environmental origins of antibiotic resistance.

Our paper titled "Why Do Antibiotics Exist?" is now available in @mbiojournal. We question the dogma that antibiotics are primarily for microbial warfare. With @fabspagnolo and Monica Trujillo. journals.asm.org/doi/10.1128/mB…

I’m really honored to be one of the recipients of this year’s Vilcek Prizes for Creative Promise. America is truly a land of opportunities. My parents immigrated to the US w/ nothing but dreams & hopes when I was young. I’m glad to be able to build a life and career here in 🇺🇸

An update on Delta, vaccination protection and viral loads from the aggregate data available, with new @PHE_uk data 1. Delta infections are characterized by very high viral loads (low Cts). When a breakthrough occurs, the load is similar to unvaccinated, but clears more rapidly

#Niclosamide has activity against Variants of Concern of #SARS_CoV_2, including B.1.1.7 and B.1.351. biorxiv.org/content/10.110… @UNION_Tx @DTUBiosustain @DTUtweet

Our new paper describes a computational framework for assessing future dissemination of antibiotic resistance genes based on the gene exchange networks of their mobile elements. @DTUBiosustain @DTUtweet @novonordiskfond @lundbeckfonden @NatureComms nature.com/articles/s4146…

Data from this study support testing of UNI91104, a promising candidate for viral respiratory infections such as COVID19, in patient trials. Transient irritation in the upper respiratory tract was the most frequent adverse event. Nasal application did not result in any AE.

Excited to share Phase 1 results from @UNION_Tx inhaled & intranasal niclosamide formulation. The good HV tolerability and broad antiviral effect opens exciting perspectives for the treatment of respiratory infections - including #COVID19 sciencedirect.com/science/articl… @DTUtweet

@UNION_Tx Excited to see Urgent Public Health Prioritization for the PROTECT-V trial that investigates UNI91103 for pre-exposure prophylaxis in patients particularly vulnerable to COVID-19.

Yesterday we announced positive data from the first part of our phase 1 trial of SYNB8802. We are developing SYNB8802 as a potential treatment for patients who have high oxalate absorption from the GI tract which causes progressive kidney damage. How did we get here? 🧵 1/9

Happy to announce that our work on broadly protective nanoparticle-based influenza vaccines has been published in Nature! rdcu.be/chpnW Supraseasonal flu vaccine = protects against seasonal flu even when that year's strain prediction is off, plus some more 1/9

The emergence of the #SARSCoV2 variants B.1.1.7 (VOC-202012/01), 501Y.V2 (B.1.351) and P.1 (B.1.1.28.1) has aroused many concerns, including worsening #COVID19 and escape from vaccine-induced immunity.

Alternative proteins will transform food, mitigate climate change and drive profits. Here's how. @BCG wef.ch/3fbPnbF

Just out @TheLancet: Largest study of reinfection, whole country of Denmark —0.65% after prior covid —Protection ~80%, lasts ≥ 7 months —Age ≥ 65 protection reduced to 47% thelancet.com/journals/lance… @SteenEtTo @uni_copenhagen @SSI_dk

🎧Podcast: Intelligente tarmbakterier behandler hjernesygdomme 🦠Mikrobiolog @moasommer fortæller om arbejdet med at udvikle skræddersyede mikrober som ‘levende medicin’ 👉bit.ly/3eFo7SI #dkforsk #sundpol

Using synthetic microbial communities mimicking the Brazilian sugarcane ethanol fermentation we reveal L. amylovorus as an industrial probiotic that may improve process yield. Our collaboration with @asanchez_lab is published in @NatureComms nature.com/articles/s4146…. @DTUtweet

Great blog post on the need for inhaled #antivirals for treatment of #COVID-19 in the community setting. fpm.org.uk/blog/inhalatio…